Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

702
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

74.6K
Overview
74.6K
Immunological Memory01:23

Immunological Memory

7.3K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
7.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

3.2K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis.

iGIE : innovation, investigation and insights·2026
Same author

Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial.

The American journal of clinical nutrition·2026
Same author

Activation-dependent lentiviruses enable antigen-specific T cell expansion and transduction.

bioRxiv : the preprint server for biology·2026
Same author

Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancer.

Cancer cell·2026
Same author

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics.

Science (New York, N.Y.)·2026
Same author

Impact of immune checkpoint inhibition on ovarian reserve.

The oncologist·2026

Related Experiment Video

Updated: Sep 30, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Elevated circulating memory T cells precede immunotherapy toxicities in melanoma.

Elisa Bello1, Michael Dougan2

  • 1UMass Chan Medical School, Worcester, MA, USA.

Trends in Cancer
|March 12, 2022
PubMed
Summary

Predicting immune checkpoint inhibitor toxicity is crucial. Lozano et al. found that CD4+ memory T cells and T cell receptor diversity indicate a higher risk of these potentially fatal inflammatory side effects.

Keywords:
cancer immunotherapy toxicitiesimmune checkpoint inhibitorsimmune-related adverse eventsmemory T cells

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K

Related Experiment Videos

Last Updated: Sep 30, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K

Area of Science:

  • Oncology
  • Immunology
  • Clinical Medicine

Background:

  • Immune checkpoint inhibitor (ICI) therapy offers significant cancer treatment benefits but is associated with potentially fatal inflammatory toxicities.
  • Identifying patients at risk for these adverse events is a critical unmet need in clinical practice.

Purpose of the Study:

  • To investigate potential biomarkers for predicting ICI-related inflammatory toxicities.
  • To explore the role of T cell populations and their diversity in the development of these adverse events.

Main Methods:

  • Analysis of circulating CD4+ memory T cells.
  • Assessment of T cell receptor (TCR) diversity in patients undergoing ICI therapy.

Main Results:

  • Circulating CD4+ memory T cell levels were found to correlate with the risk of ICI toxicity.
  • Increased T cell receptor (TCR) diversity was also associated with a higher likelihood of developing inflammatory adverse events.

Conclusions:

  • CD4+ memory T cells and TCR diversity may serve as predictive biomarkers for ICI-induced toxicities.
  • These findings suggest a significant role for CD4+ memory T cells in the initiation of ICI-related inflammatory adverse events.